LONGEVA.

Semaglutide: Side Effects Reported in Studies

This page collects the adverse effects of semaglutide that the authors of published studies described. The review rests on randomized clinical trials in adults with obesity or type 2 diabetes and on meta-analyses of those trials. Observational and pharmacovigilance reports are included where they matter and are labeled as such. It is reference material on what the literature reported, not advice on use. STEP, SELECT and SUSTAIN-6 studied clinical preparations for weekly subcutaneous administration [1][2][3][4][6][7]. Reported frequencies concern those populations and conditions; they do not establish safety for a particular marketed lyophilizate or batch. A recorded adverse event is not necessarily a drug-caused reaction.

Summary

  • Gastrointestinal effects were reported most often. In STEP 1 the authors named nausea and diarrhea as the most common events and described them as typically transient and mild to moderate [1]. Gastrointestinal events were recorded in 63.5% of participants on 2.4 mg versus 34.3% on placebo in STEP 2 [2], and in 82.2% versus 53.9% over 104 weeks in STEP 5 [3].
  • In SELECT (17,604 adults), adverse events led to stopping treatment in 16.6% on semaglutide versus 8.2% on placebo, and gastrointestinal disorders accounted for most of the difference (10.0% versus 2.0%) [4][5].
  • Overall serious adverse events were less frequent with semaglutide than with placebo in SELECT (33.4% versus 36.4%) [5]. Gallbladder disorders were slightly more frequent [5]. Retinopathy complications were higher in SUSTAIN-6 [7]. An association with optic nerve ischemia (NAION) was reported in a selected neuro-ophthalmology practice cohort [12] and Danish-Norwegian registries; the low absolute risk conclusion concerns the registry study [13].

What the studies reported

EffectModel or participantsHow often or as describedSource
Nausea, diarrhea1961 adults with obesity or overweight plus a weight-related condition, without diabetes, 2.4 mg or placebo, 68 weeksMost common events, typically transient and mild to moderate; stopping because of gastrointestinal events 4.5% versus 0.8%[1]
Gastrointestinal events overall1210 adults with type 2 diabetes, 68 weeks63.5% (2.4 mg), 57.5% (1.0 mg) versus 34.3% on placebo[2]
Gastrointestinal events overall304 adults with obesity or overweight plus a weight-related condition, without diabetes, 104 weeks82.2% versus 53.9% on placebo, mostly mild to moderate[3]
Gastrointestinal events overallMeta-analysis of 4 RCTs, 3087 adults without diabetes, at least 68 weeksRelative risk 1.47 (95% CI 1.28-1.68); mostly transient and mild to moderate[8]
Stopping because of adverse events17,604 adults with cardiovascular disease and overweight or obesity, without diabetes, mean exposure 34.2 months16.6% versus 8.2% on placebo; gastrointestinal disorders 10.0% versus 2.0%[4][5]
Gallbladder disordersSame SELECT population2.8% versus 2.3%; cholelithiasis 1.4% versus 1.1%; cholecystitis 0.6% in both groups[5]
Gallbladder and biliary diseaseMeta-analysis of 76 RCTs of GLP-1 receptor agonists (the drug class), 103,371 patientsRelative risk 1.37 (95% CI 1.23-1.52); 2.29 in weight-loss trials[10]
Dysaesthesia (altered skin sensation)1407 adults with obesity without diabetes, 72 weeks, 7.2 mg, 2.4 mg or placebo22.9%, 6.0% and 0.5% respectively[6]
Retinopathy complications3297 adults with type 2 diabetes and high cardiovascular risk, 0.5 or 1.0 mg, 104 weeksHazard ratio 1.76 (95% CI 1.11-2.78) versus placebo[7]
Acute pancreatitisMeta-analysis of 21 placebo-controlled trials, 34,721 patientsOdds ratio 0.7 (95% CI 0.5-1.2); no increased risk detected[11]
Optic nerve ischemia (NAION), observationalDanish and Norwegian registries, 61,377 semaglutide users with type 2 diabetes versus SGLT-2 inhibitor users32 events; pooled hazard ratio 2.81 (95% CI 1.67-4.75); +1.41 per 10,000 person-years[13]
Psychiatric reports, pharmacovigilance31,444 EudraVigilance reports for semaglutide, liraglutide and tirzepatide372 reports (1.18%) were psychiatric; depression 187, anxiety 144, suicidal ideation 73[15]

What the effects depended on

The STEP 1 authors wrote that gastrointestinal events subsided with time [1]. FAERS authors interpreted reported-case time-to-onset patterns as early failure; the median for pancreatitis, the strong-priority signal, was 23 days. Without an exposed-population denominator, this analysis cannot estimate clinical incidence or its change over time [14]. Dose mattered in the higher range: in STEP UP, gastrointestinal events were recorded in 70.8% on 7.2 mg, 61.2% on 2.4 mg and 42.8% on placebo, and dysaesthesia in 22.9%, 6.0% and 0.5% [6]. For gallbladder and biliary disease, the class-level meta-analysis found higher risk at higher doses (relative risk 1.56 versus 0.99 at lower doses), with longer use (1.40 versus 0.79) and in weight-loss trials (2.29 versus 1.27 in trials of type 2 diabetes or other diseases) [10]. That analysis covers all GLP-1 receptor agonists, not semaglutide alone. The dose schedules used in the studies are described in the semaglutide dosing reference.

Serious and rare events

In SELECT, serious adverse events were recorded in 33.4% on semaglutide and 36.4% on placebo, driven mainly by fewer cardiac disorders (11.5% versus 13.5%). Serious events leading to discontinuation were similar (3.6% versus 4.1%), and suicide or self-injury serious events were rare and balanced (0.11% in both groups) [5].

A 2024 meta-analysis of 23 studies with 57,911 participants concluded that the adverse event associated with semaglutide was gastrointestinal in nature (nausea and vomiting) and observed no significant differences between semaglutide and comparator groups in the other outcomes it examined [9]. For acute pancreatitis, a meta-analysis of 21 placebo-controlled trials did not find an increased risk, and the result was similar for oral, low-dose and high-dose subcutaneous regimens [11].

In SUSTAIN-6, retinopathy complications (vitreous hemorrhage, blindness, or conditions requiring treatment with an intravitreal agent or photocoagulation) were more frequent with semaglutide in people with type 2 diabetes [7]. For optic nerve ischemia (NAION), a single-center retrospective cohort reported hazard ratios of 4.28 in type 2 diabetes and 7.64 in overweight or obesity, and its authors noted that causality needs further study [12]. A Danish-Norwegian registry cohort reported a pooled hazard ratio of 2.81 and concluded that the absolute risk remains low [13].

Psychiatric adverse events made up 1.2% of EudraVigilance reports for semaglutide, liraglutide and tirzepatide combined. This is a report proportion, not patient incidence or a semaglutide-specific estimate; the symptom counts in the table also concern reports across the three drugs. The authors wrote that the severity of some reports warrants further investigation [15].

Limits of the evidence

STEP 1, STEP 2, SELECT, SUSTAIN-6 and STEP UP were funded by Novo Nordisk [1][2][4][6][7]. Trials differ in population (no diabetes in STEP 1, STEP 5 and SELECT; type 2 diabetes in STEP 2 and SUSTAIN-6), dose (0.5 and 1.0 mg in SUSTAIN-6, 2.4 mg in most weight trials, 7.2 mg in STEP UP) and length (68 weeks to 104 weeks, with a mean exposure of 34.2 months in SELECT), so frequencies from different sources are not directly comparable [1][2][3][4][6][7]. Meta-analyses pool different regimens, and the gallbladder estimate covers the whole drug class [10]. Registry cohorts and pharmacovigilance databases show associations and reports, not proven causes, and the NAION authors say so themselves [12][13]. Frequencies in the table are given as the authors reported them. SELECT targeted serious events, events leading to discontinuation and prespecified events of special interest; not all nonserious events were systematically collected [5].

FAQ

What are the most common side effects of semaglutide in studies?

Gastrointestinal effects, mainly nausea and diarrhea. In STEP 1 the authors described them as typically transient and mild to moderate [1]. In STEP 2, gastrointestinal events were recorded in 63.5% on 2.4 mg versus 34.3% on placebo [2], and a meta-analysis of four trials in adults without diabetes found a relative risk of 1.47 versus placebo, with most events not requiring discontinuation [8].

Do semaglutide side effects depend on the dose?

For some effects, yes. In STEP UP, gastrointestinal events were recorded in 70.8% on 7.2 mg, 61.2% on 2.4 mg and 42.8% on placebo, and dysaesthesia in 22.9%, 6.0% and 0.5% [6]. A class-level meta-analysis also linked gallbladder and biliary disease to higher doses and longer use [10]. The FAERS early-failure interpretation concerns onset times in reported cases, not a measured decline in patient risk; without an exposed-population denominator, clinical incidence cannot be calculated [14].

Is semaglutide linked to gallbladder problems or pancreatitis?

For the gallbladder, SELECT recorded gallbladder disorders in 2.8% on semaglutide versus 2.3% on placebo [5], and a meta-analysis of 76 trials of GLP-1 receptor agonists found a relative risk of 1.37 [10]. For acute pancreatitis, a meta-analysis of 21 placebo-controlled semaglutide trials found no increased risk (odds ratio 0.7; 95% CI 0.5-1.2) [11].

What do studies say about semaglutide and eye problems?

SUSTAIN-6 recorded more retinopathy complications with semaglutide than with placebo in people with type 2 diabetes (hazard ratio 1.76; 95% CI 1.11-2.78) [7]. Two observational cohorts reported an association with NAION: hazard ratios of 4.28 and 7.64 in a single-center study [12] and a pooled 2.81 in Danish and Norwegian registries, where the absolute risk was low [13]. Both are observational, so they do not establish cause.

See also: all side-effects references, semaglutide monograph, product page.

References

  1. Wilding JP, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183
  2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021;397(10278):971-984. https://doi.org/10.1016/S0140-6736(21)00213-0
  3. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28(10):2083-2091. https://doi.org/10.1038/s41591-022-02026-4
  4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389(24):2221-2232. https://doi.org/10.1056/NEJMoa2307563
  5. Kushner RF, Ryan DH, Deanfield J, et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity. 2025;33(3):452-462. https://doi.org/10.1002/oby.24222
  6. Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology. 2025;13(11):949-963. https://doi.org/10.1016/S2213-8587(25)00226-8
  7. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375(19):1834-1844. https://doi.org/10.1056/NEJMoa1607141
  8. Moiz A, Levett JY, Filion KB, et al. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. The American Journal of Cardiology. 2024;222:121-130. https://doi.org/10.1016/j.amjcard.2024.04.041
  9. Rivera FB, Arias-Aguirre E, Aguirre Z, et al. Evaluating the safety profile of semaglutide: an updated meta-analysis. Current Medical Research and Opinion. 2024;40(9):1495-1514. https://doi.org/10.1080/03007995.2024.2383731
  10. He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases. JAMA Internal Medicine. 2022;182(5):513. https://doi.org/10.1001/jamainternmed.2022.0338
  11. Masson W, Lobo M, Barbagelata L, et al. Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis. Endocrinología, Diabetes y Nutrición (English ed.). 2024;71(3):124-132. https://doi.org/10.1016/j.endien.2024.03.012
  12. Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology. 2024;142(8):732. https://doi.org/10.1001/jamaophthalmol.2024.2296
  13. Simonsen E, Lund LC, Ernst MT, et al. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study. Diabetes, Obesity and Metabolism. 2025;27(6):3094-3103. https://doi.org/10.1111/dom.16316
  14. Shu Y, He X, Wu P, et al. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Frontiers in Public Health. 2022;10:996179. https://doi.org/10.3389/fpubh.2022.996179
  15. Tobaiqy M, Elkout H. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database. International Journal of Clinical Pharmacy. 2024;46(2):488-495. https://doi.org/10.1007/s11096-023-01694-7